These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 15939821

  • 1. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
    Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G.
    Circulation; 2005 Jun 14; 111(23):3105-11. PubMed ID: 15939821
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers.
    Zuo XR, Zhang R, Jiang X, Li XL, Zong F, Xie WP, Wang H, Jing ZC.
    Am J Cardiol; 2012 Jun 15; 109(12):1801-6. PubMed ID: 22459309
    [Abstract] [Full Text] [Related]

  • 3. Outcomes in children with idiopathic pulmonary arterial hypertension.
    Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ.
    Circulation; 2004 Aug 10; 110(6):660-5. PubMed ID: 15289375
    [Abstract] [Full Text] [Related]

  • 4. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
    Tonelli AR, Alnuaimat H, Mubarak K.
    Respir Med; 2010 Apr 10; 104(4):481-96. PubMed ID: 20004088
    [Abstract] [Full Text] [Related]

  • 5. Pulmonary Vascular Capacitance is Associated with Vasoreactivity and Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension.
    Cheng XL, He JG, Liu ZH, Gu Q, Ni XH, Zhao ZH, Luo Q, Xiong CM.
    Lung; 2016 Aug 10; 194(4):613-8. PubMed ID: 27272652
    [Abstract] [Full Text] [Related]

  • 6. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.
    Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G, Humbert M, Simonneau G, Sitbon O.
    Eur Heart J; 2010 Aug 10; 31(15):1898-907. PubMed ID: 20543192
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.
    Am J Cardiol; 2010 May 15; 105(10):1485-9. PubMed ID: 20451700
    [Abstract] [Full Text] [Related]

  • 8. Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost.
    Wolff B, Lodziewski S, Bollmann T, Opitz CF, Ewert R.
    Am Heart J; 2007 Jun 15; 153(6):1088.e1-7. PubMed ID: 17540215
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
    Jais X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O, Simonneau G, Humbert M.
    Arthritis Rheum; 2008 Feb 15; 58(2):521-31. PubMed ID: 18240255
    [Abstract] [Full Text] [Related]

  • 10. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2007 Apr 15; 26(4):357-62. PubMed ID: 17403477
    [Abstract] [Full Text] [Related]

  • 11. Differences in the acute pulmonary vascular effects of oxygen with nitric oxide and diltiazem: implications for the long-term treatment of pulmonary arterial hypertension.
    Day RW.
    Congenit Heart Dis; 2013 Apr 15; 8(1):71-7. PubMed ID: 22891699
    [Abstract] [Full Text] [Related]

  • 12. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria.
    Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R.
    Vascul Pharmacol; 2005 Sep 15; 43(3):143-7. PubMed ID: 16061423
    [Abstract] [Full Text] [Related]

  • 13. [Clinical-hemodynamic correlation of the NYHA/WHO system in idiopathic pulmonary artery hypertension. Clinical, therapeutic and long-term prognosis implications].
    Herrera EL, Zárate JS, Solano JF, Martínez LE, Zamudio TR, Bautista EG.
    Arch Cardiol Mex; 2008 Sep 15; 78(2):148-61. PubMed ID: 18754406
    [Abstract] [Full Text] [Related]

  • 14. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
    Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G.
    Eur Respir J; 1998 Aug 15; 12(2):265-70. PubMed ID: 9727772
    [Abstract] [Full Text] [Related]

  • 15. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry.
    Douwes JM, Humpl T, Bonnet D, Beghetti M, Ivy DD, Berger RM, TOPP Investigators.
    J Am Coll Cardiol; 2016 Mar 22; 67(11):1312-23. PubMed ID: 26988953
    [Abstract] [Full Text] [Related]

  • 16. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension.
    Ruiz-Cano MJ, Escribano P, Alonso R, Delgado J, Carreira P, Velazquez T, Sanchez MA, Sáenz de la Calzada C.
    J Heart Lung Transplant; 2009 Jun 22; 28(6):621-7. PubMed ID: 19481024
    [Abstract] [Full Text] [Related]

  • 17. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV, Genthner DE, Panella MM, Rich S.
    N Engl J Med; 1998 Jan 29; 338(5):273-7. PubMed ID: 9445406
    [Abstract] [Full Text] [Related]

  • 18. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension.
    Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL.
    Eur Respir J; 2009 Jun 29; 33(6):1354-60. PubMed ID: 19213781
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.
    Halliday SJ, Hemnes AR, Robbins IM, Pugh ME, Zhao DX, Piana RN, Fong PP, Brittain EL.
    J Heart Lung Transplant; 2015 Mar 29; 34(3):312-8. PubMed ID: 25577565
    [Abstract] [Full Text] [Related]

  • 20. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
    Gerhardt F, Fiessler E, Olsson KM, Kayser MZ, Kovacs G, Gall H, Ghofrani HA, Badr Eslam R, Lang IM, Benjamin N, Grünig E, Halank M, Lange TJ, Ulrich S, Leuchte H, Held M, Klose H, Ewert R, Wilkens H, Pizarro C, Skowasch D, Wissmüller M, Hellmich M, Olschewski H, Hoeper MM, Rosenkranz S.
    Circulation; 2024 May 14; 149(20):1549-1564. PubMed ID: 38606558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.